Chemomab Therapeutics Ltd. — Form 6-K Summary
Business context and period: Filed September 30, 2026, for the month of September. This filing reports an amendment dated September 23, 2026, to the agreement for Chemomab’s proposed U.S. domestication, in connection with its proposed merger with Scipher Medicine Corporation. It does not report quarterly or annual operating results.
Key financial and transaction information
- Financial results: The filing provides no revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating financial metrics.
- Amended share-conversion mechanics: The amendment introduces a formula-based domestication exchange ratio for converting Chemomab ordinary shares, including shares represented by ADSs, and outstanding options into Chemomab Parent common stock. The stated aim is for the Combined Company to have an aggregate 10,000,000 shares outstanding immediately following closing of the Merger.
- Economics and ownership: The company says the amendment is technical and does not change transaction consideration, transaction economic value, or the relative ownership allocation between Chemomab and Scipher. It also addresses fractional shares, equity awards, and contingent value rights (CVRs).
Material changes and outlook
The Merger was previously expected to close in the fourth calendar quarter of 2026. If completed, the businesses are expected to combine under Chemomab Parent, which is expected to be renamed Scipher Medicine Corporation. The Combined Company is expected to list on Nasdaq Capital Market under ticker SCIP. Reginald Seeto is expected to serve as CEO, and Chemomab CEO and co-founder Adi Mor is expected to join the board. These are forward-looking expectations, not completed events.
The filing gives no new financial guidance or quantified outlook. It cautions that completion depends on conditions including shareholder approvals, regulatory approvals, and financing; the transaction may be delayed or may not close. Other cited risks include transaction costs and operating expenses pending closing, changes in the exchange ratio, clinical and regulatory uncertainty for both companies’ product candidates, and the Combined Company’s ability to obtain sufficient capital.
Important facts for investors to verify
- Review the full amendment and subsequent SEC filings, including the planned Form S-4 and proxy statement/prospectus, for the precise exchange-ratio formula and treatment of shares, ADSs, options, fractional shares, and CVRs.
- Check whether required shareholder and regulatory approvals are obtained, whether the related private placement financing is completed, and whether the expected Q4 2026 closing and Nasdaq listing occur.
- Confirm the final ownership structure, share count, CVR terms, and leadership arrangements in definitive transaction documents.
- Consult Chemomab’s latest filings for current financial condition, cash runway, operating expenses, and clinical-program risks; this 6-K does not provide those figures.